KalVista Pharmaceuticals (KALV) News Today $12.50 +0.25 (+2.04%) Closing price 04:00 PM EasternExtended Trading$12.49 -0.01 (-0.08%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) PT at $23.80March 25 at 1:05 AM | americanbankingnews.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Recommendation of "Buy" by AnalystsKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) has been assigned an average recommendation of "Buy" from the seven brokerages that are currently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong bMarch 23 at 4:13 AM | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 3% - Here's WhyKalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 3% - Time to Sell?March 20, 2025 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV)March 16, 2025 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV)March 16, 2025 | americanbankingnews.comKalVista Pharmaceuticals' (KALV) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday.March 15, 2025 | marketbeat.comKalVista Pharmaceuticals' (KALV) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday.March 14, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Releases Earnings Results, Misses Estimates By $0.03 EPSKalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) issued its earnings results on Wednesday. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.03).March 13, 2025 | marketbeat.comInsider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells 6,669 Shares of StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 6,669 shares of the company's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $11.97, for a total transaction of $79,827.93. Following the transaction, the chief executive officer now directly owns 287,811 shares of the company's stock, valued at $3,445,097.67. This represents a 2.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.March 11, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 6,669 SharesMarch 11, 2025 | insidertrades.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Down 18.2% in FebruaryKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) saw a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 5,830,000 shares, a decline of 18.2% from the January 31st total of 7,130,000 shares. Based on an average daily volume of 371,600 shares, the days-to-cover ratio is currently 15.7 days.March 5, 2025 | marketbeat.comKalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual MeetingMarch 3, 2025 | finance.yahoo.comKalVista Pharmaceuticals (KALV) to Release Quarterly Earnings on MondayKalVista Pharmaceuticals (NASDAQ:KALV) will be releasing earnings before the market opens on Monday, March 10, Financial Modeling Prep reports.March 3, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 2,394 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul K. Audhya sold 2,394 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $10.02, for a total transaction of $23,987.88. Following the sale, the insider now owns 102,940 shares in the company, valued at $1,031,458.80. This represents a 2.27 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 26, 2025 | marketbeat.comPaul K. Audhya Sells 2,394 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) StockFebruary 26, 2025 | insidertrades.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Buy" from AnalystsShares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) have been assigned a consensus rating of "Buy" from the seven research firms that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buyFebruary 25, 2025 | marketbeat.comKalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual MeetingFebruary 21, 2025 | uk.finance.yahoo.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 3,125 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul K. Audhya sold 3,125 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $30,687.50. Following the sale, the insider now owns 100,334 shares of the company's stock, valued at $985,279.88. This trade represents a 3.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.February 20, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 5,104 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 5,104 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $50,121.28. Following the sale, the chief executive officer now directly owns 278,855 shares of the company's stock, valued at $2,738,356.10. This represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.February 20, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 8.7% - What's Next?KalVista Pharmaceuticals (NASDAQ:KALV) Shares Up 8.7% - Time to Buy?February 20, 2025 | marketbeat.comTD Cowen Remains a Buy on Supernus Pharmaceuticals (SUPN)February 20, 2025 | markets.businessinsider.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells $30,687.50 in StockFebruary 20, 2025 | insidertrades.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest UpdateKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 7,130,000 shares, a drop of 6.1% from the January 15th total of 7,590,000 shares. Based on an average daily volume of 368,500 shares, the short-interest ratio is presently 19.3 days.February 18, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Acquires 100,000 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par acquired 100,000 shares of the business's stock in a transaction on Wednesday, February 12th. The stock was acquired at an average price of $9.23 per share, with a total value of $923,000.00. Following the transaction, the insider now directly owns 5,217,285 shares of the company's stock, valued at $48,155,540.55. This represents a 1.95 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.February 15, 2025 | marketbeat.comVenrock Healthcare Capital Par Purchases 100,000 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) StockFebruary 15, 2025 | insidertrades.comKalVista Pharmaceuticals sees $1.5m stock purchase by VenrockFebruary 15, 2025 | msn.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Acquires $37,812.18 in StockFebruary 12, 2025 | insidertrades.comInsider Buying: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Purchases 4,137 Shares of StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par acquired 4,137 shares of KalVista Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were purchased at an average cost of $9.14 per share, with a total value of $37,812.18. Following the completion of the purchase, the insider now directly owns 5,090,582 shares of the company's stock, valued at approximately $46,527,919.48. This represents a 0.08 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.February 11, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Purchases 73,649 Shares of StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 73,649 shares of the company's stock in a transaction that occurred on Friday, February 7th. The shares were purchased at an average price of $9.29 per share, with a total value of $684,199.21. Following the completion of the transaction, the insider now directly owns 5,086,445 shares of the company's stock, valued at $47,253,074.05. This represents a 1.47 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.February 11, 2025 | marketbeat.comJMP Securities Sticks to Their Buy Rating for KalVista Pharmaceuticals (KALV)February 11, 2025 | markets.businessinsider.comKalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual MeetingFebruary 10, 2025 | finance.yahoo.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE) and Supernus Pharmaceuticals (SUPN)February 4, 2025 | markets.businessinsider.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Acquires 14,562 SharesFebruary 4, 2025 | insidertrades.comInsider Buying: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Acquires 14,562 Shares of StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par bought 14,562 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were acquired at an average cost of $9.22 per share, for a total transaction of $134,261.64. Following the completion of the transaction, the insider now owns 5,012,796 shares of the company's stock, valued at approximately $46,217,979.12. The trade was a 0.29 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.February 3, 2025 | marketbeat.comVenrock Healthcare Capital Par Purchases 43,707 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 43,707 shares of the company's stock in a transaction on Thursday, January 30th. The stock was bought at an average price of $8.76 per share, for a total transaction of $382,873.32. Following the completion of the purchase, the insider now directly owns 4,986,480 shares of the company's stock, valued at $43,681,564.80. The trade was a 0.88 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.February 3, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Upgraded to "Strong-Buy" at Citizens JmpCitizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday.February 1, 2025 | marketbeat.comJMP Securities Initiates Coverage of KalVista Pharmaceuticals (KALV) with Market Outperform RecommendationFebruary 1, 2025 | msn.comJMP reiterates Kalvista stock with $19 target, sees market growthJanuary 31, 2025 | msn.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Recommendation of "Buy" from BrokeragesShares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) have earned a consensus recommendation of "Buy" from the five analysts that are presently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 12-month targeJanuary 31, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Now Covered by JMP SecuritiesJMP Securities initiated coverage on KalVista Pharmaceuticals in a research report on Friday. They issued an "outperform" rating and a $19.00 price objective for the company.January 31, 2025 | marketbeat.comKalVista initiated with an Outperform at JMP SecuritiesJanuary 31, 2025 | markets.businessinsider.comOptimistic Buy Rating for KalVista Pharmaceuticals Amid Promising Launch of SebetralstatJanuary 31, 2025 | markets.businessinsider.comJMP Securities sets $19 target for Kalvista Pharmaceuticals stockJanuary 31, 2025 | msn.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Cross Above 50-Day Moving Average - Time to Sell?KalVista Pharmaceuticals (NASDAQ:KALV) Shares Pass Above 50 Day Moving Average - What's Next?January 30, 2025 | marketbeat.comEquities Analysts Issue Forecasts for KALV FY2026 EarningsKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Cantor Fitzgerald issued their FY2026 earnings estimates for KalVista Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the specialty pharmaceutical company wiJanuary 22, 2025 | marketbeat.comKalVista granted orphan drug designation for sebetralstat by MHLWJanuary 21, 2025 | markets.businessinsider.comKalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary AngioedemaJanuary 21, 2025 | finance.yahoo.comJapan grants orphan drug status to HAE treatmentJanuary 21, 2025 | msn.comKalVista Announces Orphan Drug Designation And NDA Submission For Sebetralstat In JapanJanuary 21, 2025 | markets.businessinsider.comHennion & Walsh Asset Management Inc. Makes New Investment in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Hennion & Walsh Asset Management Inc. purchased a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 74,827 shares ofJanuary 21, 2025 | marketbeat.com Remove Ads Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address KALV Media Mentions By Week KALV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KALV News Sentiment▼0.730.68▲Average Medical News Sentiment KALV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KALV Articles This Week▼43▲KALV Articles Average Week Remove Ads Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IBRX News BEAM News VCEL News MIRM News EWTX News CNTA News KYMR News CGON News DNLI News BLTE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KALV) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KALV Stock Free KALV Stock Alerts